AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 22 - (NewsRx.com & NewsRx.net) -- Northfield Laboratories Inc. (NASDAQ:NFLD) announced that it will receive $1.4 million in designated funding for the continued development of PolyHeme, the company's human hemoglobin-based blood substitute.
The funding will be received as part of the fiscal 2005 Defense Appropriations Bill recently signed by President Bush.
"Northfield is pleased to be included in the federal government's defense appropriations," said Steven A. Gould, MD, chairman and chief executive officer. "The Department of Defense has had a long-standing interest in the development of an oxygen-carrying resuscitative fluid that would be suited for use on the battlefield, where blood is not immediately available. The Defense Appropriations Bill recognizes the need to support the development of innovative medical technologies, like Polyheme, that may help reduce the loss of American lives, both ...